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Abstract
Objectives: Permanent pacemakers are widely used in the pediatric population due to congenital and surgically acquired rhythm disturbances. The diversity and complexity of congenital heart diseases make device management a
highly individualized procedure in pediatric pacing. We are also faced with special problems in pediatric age group as
growth, children's activity and infection susceptibility. This study aimed to present our institute's experience in pediatric
and adolescent pacemaker implantation and long-term outcomes.
Methods: This cross-sectional observational study included 100 pediatric patients who visited our outpatient clinics at
Ain Shams University Hospitals for regular follow up of their previously implanted permanent pacemakers. All patients
were subjected to history taking, clinical examination, ECG recording, echocardiography and elaborate device programming. Data about device types, device components’ longevity, subsequent procedures, complications were
collected, with comparison between epicardial and endocardial pacemakers.
Results: Our study population ranged in age from 8 months to 18 years (mean 13.12 ± 5.04 years), 51 were males and 53
patients had congenital heart disease. Epicardial pacing represented 26% of our total population using only VVIR
pacemakers, while endocardial pacing represented 74% of our population with 58.1% of them being VVIR pacemakers.
First battery longevity was higher in endocardial batteries (108 months vs. 60 months, p value: 0.007). First lead longevity
was also higher in endocardial leads (105 moths vs. 58 months, p value: 0.006). Complication rate was 25%; 8 patients had
early complications (one insulation break in endocardial group). Late complications occurred in 17 patients (10 patients
had lead fracture; 9 of them were endocardial, 2 insulation breaks in endocardial leads, 3 patients from epicardial group
had lead failure of capture). In total, 16 patients had lead-related complications. There was no statistically signiﬁcant
difference between different lead models regarding lead-related complications.
Conclusion: Pacemakers in children are generally safe, but still having high rates of lead-related complications. Lead
failure of capture was more common in epicardial leads. These complications had no relation to the model of the leads.
Endocardial pacemakers showed higher ﬁrst lead and ﬁrst battery longevity compared to epicardial pacemakers.
Keywords: Permanent pacing, Pediatric age, Endocardial pacing, Epicardial pacing, Pacing complications

1. Introduction

C

ardiac devices are an effective long-term
treatment for a variety of bradyarrhythmias.
Permanent pacemakers are widely used in the
pediatric population due to congenital and surgically acquired rhythm disturbances [1,2]. The
indications for pacing in children and patients
with CHD are slightly different than in adults,

mainly reﬂecting the broad range of ages and
concomitant structural heart disease involved [3].
Permanent pacing in pediatric patients is generally safe and has a favorable long-term outcome, but
there remains a high rate of complications mainly
related to lead performance. This is of particular
concern in children who need a lifetime of pacing
with modern technology [4,5]. The choice between
endocardial or epicardial pacing is usually decided
according to the presence of complex congenital
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heart disease, type of corrective surgery and the size
of the patient [6].
Permanent cardiac pacing in pediatric patients is
performed in few cardiology centers in Egypt. So,
the current study aims to present our institute's
experience in pediatric and adolescent pacemakers
and their long-term outcomes.

2. Methods
This study was a cross-sectional observational
study. It was conducted on patients already
attending in the pacemaker follow up clinic. They
were undergoing regular routine follow up in
pacemaker follow up clinics at Ain Shams University Hospitals. These visits are done regularly to all
patients with implanted pacemakers including both
adults & pediatrics. We selected the ﬁrst 100 pediatric patients from those who presented in the clinic
during the timeline of the study. Medical ﬁles were
used for retrieving implantation data of the selected
patients. Patients older than 18 years, handicapped
or mentally retarded patients, or PPM implanted
within 6 months of the study recruitment date were
excluded from our study. Programming was done
by an experienced cardiologist who received
training on the programming of all types of cardiac
devices. All patients were evaluated once. We
enrolled in patients between July 2018 and
December 2019. All parents & adolescent patients
gave written informed consent that they accept the
participation in this study. The study was approved
by Ain Shams University ethical committee according to the ethical guidelines of the 1975 declaration of Helsinki as revised in 2008.
Full medical history was taken with special
emphasis on demographic data including age,
gender, weight, and indications of pacing, history of
CCU admission, history of surgery or catheterization, family history of the same illness. All patients
were subjected to thorough clinical examination.
We were particularly interested in comparing
epicardial and endocardial pacemakers regarding
pacemaker types, device data, ﬁrst battery & lead
longevity, second or third procedures, complications (whether early or late complications) and device interrogation.
2.1. Device data
We collected data regarding indication of pacemaker implantation (sinus node dysfunction,
congenital heart block or post-operative heart block),
age of ﬁrst implantation, ﬁrst implantation technique
whether (endocardial or epicardial), device data

List of abbreviations
CCU
Cardiac care unit
CHB
Complete heart block
CHD
Congenital heart disease
CHF
Congestive heart failure
CRT-P Cardiac resynchronization therapy pacemaker
DDD/DDDR
Dual chamber pacemaker
ECG
Electrocardiogram
LVEF
Left ventricular ejection fraction
PDA
Patent ductus arteriosus
PPM
Permanent pacemaker
VVI/VVIR
Single chamber pacemaker

including its type (VVIR or DDD), manufacturer,
model name, lead type, site of pulse generator implantation. Data about number of battery replacement, PPM replacement or device & lead extraction
procedures since ﬁrst implantation, their timing as
well as their indication, were also collected.
2.1.1. Important deﬁnitions
- Battery replacement: exchange of the pulse
generator only with keeping the previously
implanted leads in place.
- PPM replacement: exchange of the pulse generator in addition to exchanging the previously
implanted leads (whole device replacement).
- Lead extraction: removal of at least one previously implanted lead with the assistance of
specialized equipment.
Device related complications were recorded,
whether early complications which occurred in the
ﬁrst 3 months after implantation or late complications occurring after more than 3 months of
implantation.
ECG was done to all patients to assess heart rate &
rhythm, detect any arrhythmias & assess pacemaker
function. Echocardiography was done to detect
presence or absence of structural heart diseases or
congenital heart diseases. LVEF measurement by
modiﬁed Simpson's method was performed using
the standard technique [7].
2.2. Device interrogation & programming
Device interrogation & programming were performed using the appropriate programmer for battery information including voltage, battery
impedance, remaining longevity in addition to lead
integrity (impedance measurements considered
normal between 300 and 1200 Ohms) with detection
of any signs of lead fracture or insulation break.

Sensing function evaluation was done measuring
ventricular and atrial spontaneous electrograms
amplitudes (P wave & R wave amplitudes were
tested & recorded with reported normal value above
1.5mv & 5mv respectively). Pacing threshold testing
of atrial and ventricular leads was done.
2.3. Statistical analysis
Data were collected, coded, revised and entered
the Statistical Package for Social Science (IBM SPSS)
version 21. The data were presented as mean,
standard deviations and ranges for the quantitative
data with the parametric distribution. The comparison between groups with qualitative data was done
by using the Chi-square test and/or Fisher exact test
only when the expected count in any cell found less
than 5%. The comparison between two independent
groups with quantitative data and parametric distribution was done by using an independent t-test.
The comparison between more than two groups
with quantitative data was done by using One Way
Analysis of Variance (ANOVA). The conﬁdence interval was set to 95% and the margin of error
accepted was set to 5%. So, the p-value was
considered signiﬁcant as the following: p > 0.05:
Non-signiﬁcant (NS), p < 0.05: Signiﬁcant (S),
p < 0.01: Highly signiﬁcant (HS).

3. Results
3.1. Patient's clinical and demographic data
Our study included 100 patients ranging from 8
months to 18 years of age (mean 12.58 ± 5.27 years).
We had 51 males and 49 females. Forty-seven patients had structurally normal hearts, while 53 patients had congenital heart disease (Table 1). Types
of congenital heart diseases were shown in Fig. 1.
From 53 patients having congenital heart diseases,
50 patients had history of cardiac surgery for repair
of their congenital defects. Two patients had done
PDA coil closure. Only one patient in our study had
a history of a cardiac diagnostic hemodynamic
study.
3.2. Device data
Epicardial pacing represented 26% of our total
population using only VVIR pacemakers, while
endocardial pacing represented 74% of our population with 58.1% of them being VVIR pacemakers,
with a highly signiﬁcant difference between both
techniques (p-value¼<0.01). The details of device
manufacturer's data are detailed in Table 2.

Table 1. Patient clinical demographic data.
No. ¼ 100
Age (years)
Mean ± SD
Range
Gender
Female (no. %)
Male (no. %)
Weight (kg)
Mean ± SD
Range
Height (cm)
Mean ± SD
Range
Body surface area (m2)
Mean ± SD
Range
Echocardiography data EF (%)
Mean ± SD
Range
Pacing indication (no., %)
Sinus node dysfunction
Cong. CHB
Post-operative CHB

12.58 ± 5.27
0.8e18
49 (49.0%)
51 (51.0%)
48.98 ± 21.78
8e85
137.07 ± 31.74
49e172
1.35 ± 0.45
0.39e1.96
60.90 ± 6.24
44e77
2 (2.0%)
52 (52.0%)
46 (46.0%)

CHB: congenital heart block.

The mean age for epicardial pacemakers was
signiﬁcantly lower than that for endocardial pacemakers (p-value¼<0.01). The smallest weight and
height for endocardial pacing reported were 12 kg
and 69 cm, which were signiﬁcantly higher
compared to epicardial pacing (p-value¼<0.01
and < 0.01, respectively).
The devices used in our studied population were
St. Jude Medical devices in (69.0%) of patients
compared to other manufacturers (Medtronic 25%,
Biotronik 4%, Boston Scientiﬁc 2%), with no statistically signiﬁcant difference between epicardial and
endocardial devices (73.1% vs. 67.6% respectively)
(p-value ¼ 0.523) as shown in Table 2.
3.3. Device implantation & multiple procedures
data
In our study, all patients were pacemaker
dependent. The age of patients at 1st device implantation ranged from 2 months to the age of 14
years.
3.3.1. Second procedure
A total of 39 patients needed a second procedure
prior to the study; one patient with DDDR pacing
was upgraded to CRT-P due to LV dysfunction,
while 19 patients were switched from epicardial to
endocardial pacing after 3e7 years from ﬁrst implantation (Table 3).
Device battery was replaced in 12 patients due to
battery end of life and the pacing system was
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Fig. 1. Types of congenital heart diseases. ASD: atrial septal defect, CAVC: common AV canal, D-TGA: dextro-transposition of great arteries, L-TGA:
levo-transposition of great arteries, PDA: patent ducts arteriosus, TOF: Tetralogy of Fallot, VSD: ventricle septal defect.

replaced in 9 patients due to lead problems and
battery end of life with a device age ranging between 2 and 12 years after device implantation with
mean of 5.92 ± 3.04 years, ﬁve of them were
switched from epicardial to endocardial pacing. Two

patients with endocardial pacing had successful
lead extraction to allow for implantation of a new
device with new leads, and two patients had
changed their leads with epicardial pacing due to
lead failure of capture (Table 3).

Table 2. Device data at time of follow up.

Type
Age (years)
Weight (kg)
Height (cm)
Body surface area (m2)
Manufacturer

Model Name

Model Lead

VVIR
DDDR
Mean ± SD
Range
Mean ± SD
Range
Mean ± SD
Range
Mean ± SD
Range
ST. Jude Medical
Medtronic
Boston Scientiﬁc
Biotronik
Microny
Endurty
Relia
Sensia
Verity
Sustain
Talos
Tendril
Capsureﬁx
Capsure EPI
Boston angipty
Salox SR53

Epicardial

Endocardial

No. ¼ 26

No. ¼ 74

26 (100%)
0 (0.0%)
6.10 ± 2.23
0.8e8
20.85 ± 4.81
8e25
101.81 ± 28.26
49e128
0.76 ± 0.19
0.39e0.94
19 (73.1%)
7 (26.9%)
0 (0.0%)
0 (0.0%)
4 (15.4%)
9 (34.6%)
3 (11.5%)
4 (15.4%)
2 (7.7%)
4 (15.4%)
0 (0.0%)
15 (57.7%)
2 (7.7%)
9 (34.6%)
0 (0.0%)
0 (0.0%)

43 (58.1%)
31 (41.9%)
14.85 ± 3.97
4e18
56.77 ± 19.00
12e85
148.76 ± 20.52
69e172
1.52 ± 0.37
0.48e1.96
50 (67.6%)
18 (24.3%)
2 (2.7%)
4 (5.4%)
2 (2.7%)
36 (48.6%)
0 (0.0%)
17 (23.0%)
7 (9.5%)
8 (10.8%)
4 (5.4%)
50 (67.6%)
16 (21.6%)
0 (0.0%)
2 (2.7%)
6 (8.1%)

Test value

p- value

15.785*

<0.01

10.639

<0.01

9.504

<0.01

9.054

<0.01

9.935

<0.01

2.245

0.523

16.873*

0.010

30.789*

<0.01

Table 3. Types of implantation procedures including indications of second & third procedures.
No. ¼ 100
Age of ﬁrst implantation (years)
Mean ± SD
Range
Device Dependency
Route of implantation
Epicardial
Lt. subclavian
Rt. Subclavian
Timing of second procedure (years)
Mean ± SD
Range
Total number of leads
Number of functioning lead (%)
Number of non- functioning lead (%)

5.29 ± 3.99
0.2e14
100 (100.0%)
26 (26.0%)
59 (59.0%)
15 (15.0%)
5.92 ± 3.04
0.60e12.00
147 (100%)
133 (90.5%)
14 (9.5%)

Type of second &third procedures

Epicardial
N ¼ 26

Endocardial
N ¼ 74

Duration (years)
From previous implantation

2nd procedure n ¼ 39
Pacing system replacement n ¼ 9
Battery replacement n ¼ 12
Lead replacement n ¼ 2
PM upgrading to CRT-P n ¼ 1
Switch from epicardial to endocardial pacing n ¼ 19
History of lead extractions n ¼ 2
3rd procedure n ¼ 7
Pacing system replacement n ¼ 7
PM upgrading VVI to DDD n ¼ 4

25 (25%)
4 (4%)
4 (4%)
2 (2%)
0

14 (14%)
5 (5%)
8 (8%)
0 (0%)
1 (1%)

0
0
0 (0%)
0 (0%)

2
7 (7%)
7 (7%)
4 (4%)

3e8
2e12
3e8
0.6
8
3e7
3e4
2e8
2e8
7e8

3.3.2. Third procedure
A total of 7 patients needed a third procedure
prior to the study within 2e8 years from 2nd procedure. Four of them needed pacing system upgrade from VVI pacing to DDD with ventricular lead
replacement due to lead fracture; while the other 3
patients needed pacing system replacement only
due to insulation breaks within 2e3 years which
resulted in premature battery depletion (Table 3).
Battery and pacing system replacements were
signiﬁcantly higher in the VVIR group (p-value¼<0.01, 0.018 respectively). The timing of second
procedures in DDDR patients was signiﬁcantly later
compared to VVIR patients with mean timing of
7.91 ± 2.20 years vs. 5.19 ± 3.01 years respectively
with (p-value ¼ 0.008).
Meanwhile, third procedures in the form of pacing system replacement were only done in VVIR
group.
3.4. Device battery and lead measurement data
Lead measurements including lead impedances,
pacing thresholds and sensing function measurements of all ventricular leads, were similar with no
statistical difference between epicardial and endocardial group. The longevity of some device batteries was short because of lead problems

necessitating pacing system replacement; three patients had insulation breaks needed pacing system
replacement after 2e3 years and one patient with
epicardial PPM had lead fracture after 2 years
needed to replace the device after 2 years.
3.5. First battery longevity
The longevity of PPM batteries (endocardial Vs
epicardial), independently from pacing mode and
battery manufacturer is presented by Kaplan-Meier
survival estimate curve (Fig. 2).
There was statistically signiﬁcant difference
among the two survival curves with median of 108
months in endocardial batteries compared to a median of 60 months in epicardial batteries, using (Logrank chi-squared ¼ 15.408, df ¼ 1, p-value ¼ 0.007*).
3.6. First ventricular lead longevity
The longevity of ventricular leads independently
from pacing mode is represented by Kaplan-Meier
survival curve in endocardial versus epicardial
leads. There was statistically signiﬁcant difference
among two survival curves with median of 105
months in endocardial leads compared to median of
58 months in epicardial leads using (Log-rank chisquared ¼ 18.965, df ¼ 1, p-value ¼ 0.006*) (Fig. 3).
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Fig. 2. Kaplan-Meier survival curves in endocardial versus epicardial pacemakers' batteries (Log-rank chi-squared ¼ 15.408, df ¼ 1, pvalue ¼ 0.007*).

3.7. Complications
A total of 25 patients (25%) of our studied population developed complications including 16 leadrelated complications (Table 4). Early complications
occurred in only 8 patients (all from endocardial
group) with only one lead-related complication

(insulation break which occurred one month after
endocardial pacemaker implantation).
As far as late complications, ten patients had lead
fractures within 1 yeare8 years after device implantation due to external trauma, only one of them
was epicardial. Three patients developed lead failure of capture after 6 months with epicardial

Fig. 3. Kaplan-Meier survival curves in endocardial versus epicardial ventricular leads (Log-rank chi-squared ¼ 18.965, df ¼ 1, p-value ¼ 0.006*).

Table 4. Complications among studied patients.

Early complications
Superﬁcial infection n., (%)
Painful pocket n,.(%)
Pocket hematoma n., (%)
Trauma to apex of lung n., (%)
Insulation break n., (%)
Timing (month)
Late complications
Lead fracture n., (%)
Timing (years)
Mean ± SD
Lead failure of capture n., (%)
Timing (months)
Insulation break n., (%)
Timing (months)
Others

Epicardial
No. ¼ 26

Endocardial
No. ¼ 74

Test value

p- value

0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
e

2
2
2
1
1
1

(2.7%)
(2.7%)
(2.7%)
(1.35%)
(1.35%)

0.717
0.717
0.717
0.355
0.355
e

0.397
0.397
0.397
0.551
0.551
e

1 (3.8%)
2
2.00 ± 0.00
3 (11.5%)
6
0 (0.0%)
e
0 (0.0%)

9 (12.2%)
1e8
3.56 ± 2.65
0 (0.0%)
e
2 (2.7%)
6
2 (2.7%)

1.478
e

0.224
e

8.803
e
0.717

0.003
e
0.397

0.717

0.397

pacemakers. Two patients had insulation breaks 6
months after pacemaker implantation (both were
endocardial).
Other late complications included developing LV
dysfunction in one patient after 8 years with dual
pacemaker device due to prolonged RV pacing
which was upgraded to CRT device. Another patient
developed psychological problems.
As regards lead model, there was no statistically
signiﬁcant difference between different lead models
as regards lead related complications as shown in
Table 5.

4. Discussion
Treatment with permanent pacemakers has
signiﬁcantly improved survival in patients with lifethreatening bradyarrhythmias [8]. However,
complication rates and incidence of infection appear
to be greater in children than adults [9].
Pediatric population represent a unique subset of
patients with special characteristics including
anatomical variations depending on the type of
CHD, small vascular access, somatic growth, higher
frequency of infections and traumatic events making them more prone to complications.

Still, pacemaker implantation in children and
adolescents is a procedure with a generally favorable outcome. The indications for pacing in children
and patients with CHD are slightly different than in
adults, mainly due to differences in age groups and
concomitant structural heart diseases involved. The
natural history of bradyarrhythmias in these palliated or repaired CHD patients and the speciﬁcs of
surgical approach are major determinants inﬂuencing the need for pacing. In our study a big proportion of patients (53%) had CHD and a 46% of
patients had postoperative CHB.
Epicardial pacing is usually established because of
either cardiac anatomy or small body size. In our
study, epicardial pacing was only limited to small
children, single ventricle physiology, or early postoperative CHB. Also, patients who received endocardial pacing in our study were signiﬁcantly older
& bigger in size compared to patients who received
epicardial pacemakers. The youngest age, smallest
size (i.e. weight and height) for endocardial pacing
were 4 years, 12 kg and 69 cm, respectively, which
showed signiﬁcantly higher values compared to
epicardial pacing (p-value¼<0.01, <0.01 and < 0.01,
respectively).

Table 5. Difference between model leads according to complications.

Lead fracture
Lead failure of capture
Insulation break

Tendril

Capsureﬁx

Capsure EPI

Others

No. ¼ 65

No. ¼ 18

No. ¼ 9

No. ¼ 8

8 (12.3%)
3 (4.6%)
3 (4.6%)

0 (0.0%)
0 (0.0%)
0 (0.0%)

0 (0.0%)
0 (0.0%)
0 (0.0%)

2 (25.0%)
0 (0.0%)
0 (0.0%)

P-value > 0.05: Non signiﬁcant; P-value < 0.05: Signiﬁcant; P-value < 0.01: Highly signiﬁcant.
a
Chi-square test; $: One Way ANOVA test.

Test value

p-value

5.385a
1.665a
1.665a

0.146
0.645
0.645
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In our study, the lowest weight for endocardial
pacing was a body weight of 12 kg due to concerns
about the development of venous thrombosis
resulting from disproportion between vessel and
lead size in smaller patients as well as the lifelong
need for permanent pacing in these patients. In our
institute, we believe that endocardial pacing could
be preferable due to better lead & battery performances in older pediatric population.
Despite recent technical progress, pacing leads
remain the weakest point of the permanent pacing
system, especially in a growing patient. In our study
the complication rate was 25% and more than half of
it was lead-related complications or failure (16%)
that necessitated re-intervention and lead abandonment in the majority of cases. Nearly similar
rates of complications were demonstrated in similar
studies on the same age group [10e12].
In our study there was no statistical difference
between endocardial & epicardial pacing in lead
related complications except for lead failure of
capture which was signiﬁcantly higher in epicardial
pacemakers (p ¼ 0.003). This might be related to the
limited experience of some of cardiac surgeons with
epicardial pacing in this age group. These ﬁndings
were similar to what was found previously in a
similar study [13] that showed higher lead failure in
epicardial group.
One of the most serious complications encountered in epicardial pacemakers is the development
of coronary artery compression with epicardial
leads. It can lead to potentially lethal outcomes
including sudden cardiac arrest [14]. Although it is
thought to be a rare complication, a higher incidence (5.5%) of coronary compression caused by
epicardial leads was found in a patients’ cohort
which was noted by either coronary angiography
and/or computed tomography (CT) of the coronary
arteries [15].
Our study showed that there was no relation between lead model and incidence of lead related
complications. Although Tendril leads showed a
higher incidence of complications (8 lead fractures, 3
failures of capture, 3 insulation breaks) among all
leads in this study, but still it did not reach statistical
signiﬁcance. It is the ﬁrst study in literature to
address the issue of the relation between lead model
and occurrence of lead related complications, our
hypothesis was trying to see if there's a relation
between structural properties of the lead and incidence of lead related complications.
Non elead related complications were only seen
in endocardial devices including early pocket hematoma, superﬁcial infection, painful pocket and
trauma to apex of lung during venous puncture and

late LV dysfunction, which required upgrading to
CRT.
In our study, the longevity of ventricular leads,
independently from pacing approach was signiﬁcantly longer in endocardial ventricular leads which
coincides with the ﬁndings of similar studies in
literature that reported better longevity of endocardial leads in infants [10,13,16].
In contrast Samir et al. [17] proven no signiﬁcant
difference in survival between epicardial and
endocardial leads and this discrepancy in results
might be explained by small number of patients
included in this study (32 patients). Also, in a
retrospective review chart on 158 epicardial leads,
lead survival at 10 years was 92.4%, with only 7.5%
lead failure (due to lead failure) [18].
The probable reasons behind better performance
of endocardial leads might include trauma or traction imposed on epicardial leads by thoracoabdominal movement and the numerous cardiac
operations that patients with CHD often undergo
with consequent presence of inﬂamed or scarred
epicardium.
Also, in our study the battery longevity, independently from pacing mode and battery manufacturer, showed signiﬁcantly longer median
endocardial batteries longevity. Similar results were
shown in different previous studies with the same or
even longer longevity for endocardial batteries
[12,19].
In our series, a longer average endocardial battery
survival compared to epicardial ones could be
explained by the fact that the patients in the
epicardial group were signiﬁcantly younger
demanding a higher pacing rate, and in this group,
the number of patients with operated congenital
heart disease was higher assuming an epicardial
surface with variable degrees of ﬁbrosis from scar
tissue formation or pericardial adhesions causing
higher stimulation thresholds. These two factors
may contribute to early battery depletion, too.
The patient's individual characteristics is the basis
upon which the decision on whether to implant
either endocardial or epicardial leads, rather than
on different technical aspects as lead performance
or longevity. Other factors should be considered, as
preservation of vascular access, expected operations
or reoperations and the spacial considerations for
leaving a pacing lead reserve to compensate the
patient's growth, when choosing an acceptable
route for pacemaker [18].
Although Konta et al. conducted a study that
proved that transvenous pacing in infants weighing
less than 10 kg is favorable because it showed better
short and long clinical outcomes (in patients

weighing less than 5 kg, subclavian vein occlusion
was an important complication) [20], but actually
these data cannot be generalized in general practice.
Even the largest congenital heart centers do not
have enough volume of patients or enough practice
variation to determine optimal device use for each
type of pediatric or congenital heart patient [21].
However, the emergence of leadless pacemakers’
technology offers a promising tool for effective pacing and avoiding problems that are sometimes
encountered from epicardial & endocardial pacing
discussed previously [22,23]. In a retrospective review by Breatnach et al. in 2020 on leadless pacemaker in children, they concluded that it is feasible to
implant a leadless pacemaker in pediatric patients.
Of course, these data are encouraging, but further
studies and long-term follow-up are needed to
ensure device longevity and complication rates [24].
Study Limitations:
1. The results of this study cannot be generalized
due to marked heterogenicity of the underlying
diseases and the variety of the age of patients.
2. The study presented only one single medical
center experience.
3. The study included a limited number of cases.

5. Conclusion
Pacemakers in children are generally safe with
favorable long-term outcomes. But still, we found
high rates of complications; mainly lead-related.
Epicardial pacemakers were associated with higher
incidence of lead failure of capture when compared
to endocardial pacemakers. These lead-related
complications had no relation to the model of the
leads. First battery longevity was higher in endocardial batteries. First lead longevity was also higher
in endocardial leads.
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